agilon health, inc.

source: coverage-next-full ticker: AGL company: agilon health, inc. step: 01 title: Business Model & Overview created: 2026-06-04

Step 01 — Business Model & Overview: agilon health, inc. (AGL)

1. Company Summary

agilon health, inc. (NYSE: AGL) is a value-based care (VBC) enablement company that partners with independent primary care physician (PCP) groups to manage Medicare Advantage (MA) beneficiaries under a full-risk, global capitation model. Rather than owning clinics or employing physicians, agilon provides a platform — including payer contracting infrastructure, technology analytics, care management programs, and operational support — that allows existing community physicians to bear and benefit from full MA risk. [S1][S2]

Elevator pitch: agilon transforms fee-for-service community primary care physicians into capitated Medicare Advantage partners, keeping patients healthy and capturing the gap between capitation premiums and actual medical costs as "medical margin."

2. Value Chain Layer Map

Medicare Advantage Plans (Humana, UHC, BCBS, Aetna, etc.)
    │
    │  Per-member-per-month (PMPM) capitation payments
    ▼
agilon health Platform
    │  • Global capitation contracts with MA plans
    │  • Technology platform (analytics, risk-adjustment coding support)
    │  • Care management programs (high-risk patient identification)
    │  • Operational support (billing, quality, payer relations)
    │  • Shared financial risk structure with physician groups
    ▼
Physician Partner Groups (~30 independent groups, 12 states)
    │  • Primary care physician panels take on full financial risk
    │  • Revenue = capitation PMPM × covered members
    │  • Medical margin = capitation revenue − total medical costs
    ▼
Patients (Medicare Advantage beneficiaries, ~511K covered lives, FY2025)

Revenue flow: MA plans pay agilon's physician partner entities a fixed PMPM capitation for each enrolled member. agilon recognizes this full capitation as its revenue. Medical costs (hospitalizations, specialist care, pharmacy, etc.) are subtracted to calculate Medical Margin — the economic "gross profit" of the business. agilon receives a platform fee from the physician group's net economics; the physician group retains operating income after agilon's fee. [S2]

3. Business Model Components

3a. Risk-Based Enablement (RBE) Structure

The RBE structure allows agilon to consolidate full capitation revenue while keeping physicians autonomous — a critical differentiator vs. employed-physician models (Oak Street Health, ChenMed) and fee-for-service enablement models (Privia Health). [S8]

3b. Revenue Mechanics

• Revenue = Capitation PMPM × Total MA Members × 12 months
• PMPM rates are set annually by CMS through the MA bidding process, then negotiated between the MA plan and agilon's RBE
• Revenue risk-adjustment: capitation is adjusted for member acuity (HCC risk scores); risk-adjustment true-ups have been a material negative item in FY2024 and FY2025
• Part D (prescription drug) is included in capitation — a new and material cost driver following the Inflation Reduction Act changes effective 2024

3c. Medical Margin (Economic Gross Profit)

Capitation Revenue
  − Total Medical Costs (hospitalizations, specialists, pharmacy, Part D)
= Medical Margin

Medical Margin %  =  Medical Margin / Revenue

[S1][S2]

4. Geographic & Partnership Footprint

Strategy: agilon exited underperforming markets (notably Hawaii and California in FY2023) and continues rationalizing partnerships. FY2026 guidance assumes members shrink to ~430K as additional underperforming markets/contracts exit. [S2][S6]

5. Revenue Concentration

agilon's top MA plan partners are not individually disclosed, but Humana, UnitedHealth Group, Aetna (CVS), and BCBS affiliates collectively represent the majority of capitation revenue. Single-plan concentration risk is moderated by multi-payer contracting in most markets, but MA plan consolidation is a monitoring item. [S2]

6. Competitive Positioning

Key moat claim: Physician stickiness — once a physician group takes capitation risk via agilon's platform, switching costs are high (rebuilt payer relationships, analytics dependencies, working capital support). [S8]

7. Source Index

source: coverage-next-full ticker: AGL company: agilon health, inc. step: 04 title: Financial Quality & Adversarial Sweep created: 2026-06-04

Step 04 — Financial Quality: agilon health, inc. (AGL)

1. Income Statement Quality Assessment

Revenue Recognition

• Revenue recognized on a gross basis (full capitation PMPM × members) per ASC 606
• Capitation revenue is monthly, straight-line; no material timing distortions
• Risk-adjustment settlements are estimated and trued up quarterly; FY2024 and FY2025 saw material adverse true-ups ($37M and $48M respectively) — this is NOT a recognition distortion, it reflects the genuine actuarial uncertainty in CMS risk-adjustment methodology [S2]
• Quality: CLEAN on recognition method; elevated estimation risk on risk-adjustment true-ups is disclosed prominently

Medical Cost Accruals

• agilon records IBNR (Incurred But Not Reported) claims liability based on actuarial estimates
• IBNR balance: FY2024 $~460M → FY2025 $~502M
• Reserve development (adverse vs. favorable) has been a persistent negative in FY2024–FY2025
• Quality: WATCH — IBNR adequacy is the most critical financial reporting risk; management has a track record of underestimating medical costs in recent years

Non-GAAP Adjustments

• Adjusted EBITDA excludes: SBC ($50–55M/yr), D&A ($35M/yr), restructuring charges (~$15M in FY2025), legal/investigation costs
• SBC is large relative to the company's scale (~$50M on a ~$5.9B revenue base but very large relative to the ~-$57M medical margin in FY2025)
• Quality: MODERATE CONCERN — Adjusted EBITDA in FY2025 ($-230M) is much better than GAAP loss ($-356M); the adjustments are standard but SBC is not trivial

2. Balance Sheet Quality

Capital structure note: AGL is effectively equity-funded with minimal traditional debt. However, the claims payable (IBNR) represents a contingent liability that could require cash payment materially in excess of estimates if adverse development continues. The equity base is nearly zero; another year of FY2025-magnitude losses would require external capital. The FY2026 turnaround is therefore existentially important. [S1][S2]

Reverse stock split (March 31, 2026, 1:25): Executed to maintain NYSE listing compliance — the stock had fallen below the $1.00 minimum bid price. This is a material signal of the severity of the FY2025 crisis, not just cosmetic. [S6]

3. Cash Flow Quality

FY2025 FCF of -$205M represents the worst cash burn year. Management guided FY2026 cash burn to dramatically narrow given EBITDA inflection. [S1]

Working capital note: Capitation payments are received monthly in advance; medical costs are paid with a lag. This creates a structural working capital benefit in growth phases but can reverse during membership declines as run-out claims must still be paid on departing members.

4. SBC Analysis

SBC as % of revenue is low, but as % of medical margin it is extremely high in FY2024–2025. SBC is a significant cost to equity holders even if excluded from Adj. EBITDA. [S1]

5. Adversarial Research Sweep

5a. Securities Class Action (Active)

Filed: December 31, 2025 Class period: February 2, 2024 – August 4, 2025 Allegations: The complaint alleges AGL misled investors about the sustainability of its medical margin and the severity of deteriorating medical cost trends during the class period. Specifically, plaintiffs allege AGL knew or should have known that: (1) Medicare Advantage medical costs were trending significantly above estimates; (2) risk-adjustment true-ups would be materially adverse; (3) Part D IRA changes would materially impair profitability — and failed to timely disclose this risk. The CEO departure on August 4, 2025 (simultaneous with guidance suspension) serves as the alleged "corrective disclosure" event.

Assessment: The allegations are legally plausible — the abruptness of the FY2025 guidance suspension and CEO departure is facially unusual. However, AGL's core defense is that medical cost deterioration in MA was industry-wide (HUM, CVS, ELV all experienced elevated MA costs in 2024–2025) and was not predictable with certainty. Securities class actions in healthcare frequently settle; material cash outflow is possible but the timeframe is typically 2–4 years. [S6]

5b. Short Seller History

No major organized short-seller campaign against AGL was identified. Short interest peaked pre-reverse-split at ~26.7M equivalent shares (~6% of post-split float equivalent) and had substantially compressed by May 2026 to ~640K shares (0.8 days to cover). The compression occurred as FY2026 early results recovered. No SEC investigation publicly disclosed as of research date. [S5]

5c. Accounting Red Flags Assessment

5d. Management Credibility Events

Net credibility assessment: The prior management team's credibility is compromised by the FY2025 earnings miss severity. New CEO O'Rourke's first full guidance cycle (FY2026) will be a critical test. Q1 2026 beat ($149M medical margin vs. ~$120M implied guidance) is a positive first data point. [S6]

6. Key Financial Quality Adjustments for Modeling

1. IBNR adequacy: Add 5–10% IBNR development risk haircut to medical margin estimates in scenarios
2. SBC: Treat as real economic cost in bear/base case analysis (reduces true profitability by ~$50M/yr)
3. Reverse split adjustment: All per-share historical data post-split is retroactively adjusted (÷25); verify all per-share figures from databases use the adjusted basis
4. Part D tail: FY2026 contracts explicitly reprice Part D; the risk should diminish, but one more year of adverse development is a monitoring item

7. Source Index